Latest news with #Spota
New York Post
2 days ago
- New York Post
Ex-Long Island DA jailed for corruption resurfaces as part-time, 83-year-old law clerk
He went from Suffolk County's top prosecutor ruling with an iron-fist, to a felon, to a part-time paper pusher. Disgraced former Suffolk District Attorney Thomas Spota, who was canned on corruption charges and sentenced to five years for helping cover up the brutal beating of a handcuffed suspect — has quietly rebranded as a clerk for a Long Island law firm. Spota, now 83 and disbarred, is now working part-time under the supervision of Hauppauge-hotshot criminal defense attorney Anthony LaPinta, who previously defended him in court. Advertisement 3 Ex Suffolk County district attorney Thomas Spota walking out of the federal court building in Central Islip New York after his hearing in 2018. New York Post LaPinta's office confirmed to The Post that Spota has been working as an administrative clerk in the firm since last August, shortly after he was moved from federal prison in Danbury to community confinement. 'Mr. Spota has been under my direct supervision as an administrative clerk in my law office during his work-release designation and current supervised release sentence,' LaPinta told Newsday. Advertisement Spota does administrative work as a 'nonlawyer administrative clerk' for about 10 to 15 hours per week for the firm and will remain on its payroll until at least the end of his supervised release, according to LaPinta. In 2019, Spota and his former top anti-corruption deputy, Christopher McPartland, were both convicted of conspiracy, obstruction, witness tampering and helping to cover up the savage 2012 assault of burglary suspect Christopher Loeb inside a Suffolk precinct. 3 Mug shot of Christopher Loeb who was charged with Criminal Mischief 3rd Degree, Reckless Endangerment 2nd Degree, Unlawfully Fleeing a Police Officer, Driving While Ability Impaired by Drugs, and multiple vehicle and traffic infractions. PIO Then-police Chief James Burke and three detectives were said to have carried out the beating. Advertisement Loeb was allegedly handcuffed and manically beaten by the four officers inside a Suffolk police station after the suspect broke into Burke's car and stole the police chief's dildo and porn stash to sell for drugs. Burke was sentenced to nearly four years for the beating in 2016. He now faces another stint in prison after he was busted for soliciting sex, and even masturbating in front of a plainclothes ranger at 10 a.m. in Vietnam Veterans Memorial Park in Farmingville back in 2023. 3 James Burke is arraigned in front of Judge Cheng in the Cohalan Court Complex located at 400 Carleton Ave., Central Islip, New York. Dennis A. Clark Spota's office was later convicted of trying to bury the beating to shield his long-time friend, and sentenced to four years after Burke's conviction. Advertisement In 2020, Spota was sentenced to five years in prison and disbarred. At his sentencing, he told the court he felt deep shame for the damage he caused. 'I've also left [my family] with a shattered legacy and the stain of being a convicted felon.'
Business Upturn
13-05-2025
- Business
- Business Upturn
Eleva Appoints Donato Spota as Chief Financial Officer
By GlobeNewswire Published on May 13, 2025, 11:30 IST Freiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial Officer (CFO) and Managing Director. Mr. Spota brings to Eleva profound expertise in complementary business areas including strategic finance, investor relations, business development and international capital markets transactions. Danielle Püschel, currently serving as CFO, is appointed as Chief Accounting Officer. 'Eleva continues to strengthen its leadership team in line with the growing maturity of our proprietary development activities and steady progress in commercializing our technology platform. It is a pleasure to welcome Donato, whose proven experience in financial management of rapidly growing companies, makes him the ideal candidate to help us successfully navigate the ongoing transformation of Eleva,' commented Björn Cochlovius, Ph.D., Chief Executive Officer and Managing Director of Eleva. 'I also want to express my special thanks to Danielle Püschel for her commitment and leadership over the last 16 years at Eleva. The entire team is glad Danielle will continue her career with the company.' Mr. Spota is a senior executive with more than 25 years of international pharmaceutical industry experience. In his previous position as CFO of Hansa Biopharma, a Nasdaq Stockholm-listed biopharmaceutical company, he supported the progress of Hansa Biopharma's R&D pipeline and its transformation to a commercial-stage company by contributing to the corporate business and financial strategy and securing growth financing in excess of USD 200 million. Prior to joining Hansa Biopharma, Mr. Spota was CFO at Basilea Pharmaceutica AG, a Swiss-listed biopharmaceutical company. Mr. Spota held other senior financial leadership positions, including Global Head of Finance & Services and Head of Global Controlling at Basilea. Mr. Spota holds a degree in Information Technology and an in Business Administration from the HfWU University Nürtingen-Geislingen, Germany. Donato Spota added: 'Eleva is accelerating and expanding both of its core business activities in proprietary drug development and high-value product partnerships based on our transformative technology platform. I'm looking forward to working closely with Björn and the leadership team to help refine and successfully execute Eleva's growth strategy for both strategic pillars of this exciting business.' ABOUT ELEVA Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biologics based on a breakthrough moss-based technology platform. The company's proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. Dry AMD has been selected as the second indication. The company's aGal (RPV-001) program to treat Fabry disease has completed a positive Phase 1b clinical trial. All programs are sourced from Eleva's transformative moss-based technology platform, which allows lab to GMP-scale manufacturing of previously undruggable human proteins with tremendous therapeutic potential. MEDIA CONTACTS INVESTOR CONTACT Attachments 13MAY2025_Eleva_CFO_Appointment_ENG_FINAL Donato Spota Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
